# TruAge CEO Stephanie Sikorski Joins CSP C-Store Cannabis Board > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-retail-access-convenience-stores/ > **Published:** 2026-03-12T17:56:58-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:08:30-04:00 > **Clinical Summary:** Explore cannabis retail access convenience stores and the impact on patient accessibility and clinical practice with TruAge CEO's new board role. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyIndustryTHC Why This Matters This appointment reflects growing industry momentum to expand cannabis retail access through convenience stores, which could significantly increase patient accessibility to cannabis products but also raises clinical concerns about normalization and oversight of product quality and potency labeling. Clinicians should monitor regulatory developments in their states regarding convenience store cannabis sales, as these changes could affect patient education conversations and the prevalence of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) among their populations. The board’s focus on THC regulations and retailer education is relevant to clinical practice because standardized labeling and retailer training directly impact patients’ ability to make informed dosing decisions and understand product consistency. Clinical Summary This article announces that TruAge’s CEO has joined the Cannabis Sober Partnership’s convenience store board, which advocates for regulatory frameworks allowing THC product sales in traditional retail settings while promoting education among suppliers, retailers, and consumers. The board’s focus on expanding distribution channels through convenience stores represents a significant shift in cannabis accessibility and market structure that will likely increase patient exposure to cannabis products and require clinicians to be prepared for patient inquiries about over-the-counter or widely available cannabis options. As cannabis becomes more normalized and accessible in mainstream retail environments, clinicians should anticipate increased patient use and be equipped to discuss risks, benefits, drug interactions, and appropriate medical applications regardless of whether patients obtain products through dispensaries or convenience stores. This regulatory and market development underscores the importance for prescribing clinicians to maintain current knowledge about cannabis products, potency, formulations, and legal availability in their jurisdictions to provide informed guidance to patients. Dr. Caplan’s Take “What concerns me clinically is that convenience store distribution—driven by retail expansion rather than medical outcomes—will inevitably attract patients who haven’t had proper screening for contraindications like undiagnosed cardiac arrhythmias or drug interactions, while simultaneously normalizing cannabis as a commodity rather than a medication requiring informed consent.” Clinical Perspective While industry expansion of cannabis retail into convenience stores may increase accessibility and normalize the product, healthcare providers should be aware that this shift could complicate patient counseling and risk stratification, particularly for vulnerable populations who may not anticipate cannabis purchase opportunities in routine shopping environments. The advocacy for THC regulations permitting convenience store sales reflects commercial interests that may not align with public health priorities such as preventing youth access, reducing impulsive purchasing, or maintaining clear separation from other consumer goods. Providers should recognize that convenience store placement—unlike dedicated dispensaries with trained staff—may reduce opportunities for informed counseling about potency, drug interactions, and population-specific risks such as [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) or exacerbation of psychotic symptoms. Given the evolving regulatory landscape, clinicians are encouraged to maintain updated knowledge of local cannabis availability and retail models in their communities, and to proactively discuss [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and purchasing patterns during routine substance use screening to better understand their patients’ actual 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+TruAge+CEO+Stephanie+Sikorski+joins+the+CSP+C-Store+Cannabis+Board+%40drcaplan&url=https%3A%2F%2Fwww.cspdailynews.com%2Fcbdhemp%2Ftruage-ceo-stephanie-sikorski-joins-csp-c-store-cannabis-board)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.cspdailynews.com%2Fcbdhemp%2Ftruage-ceo-stephanie-sikorski-joins-csp-c-store-cannabis-board)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+TruAge+CEO+Stephanie+Sikorski+joins+the+CSP+C-Store+Cannabis+Board+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.cspdailynews.com%2Fcbdhemp%2Ftruage-ceo-stephanie-sikorski-joins-csp-c-store-cannabis-board)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.cspdailynews.com/cbdhemp/truage-ceo-stephanie-sikorski-joins-csp-c-store-cannabis-board](https://www.cspdailynews.com/cbdhemp/truage-ceo-stephanie-sikorski-joins-csp-c-store-cannabis-board) Further Reading Evidence Watch[`Cannabidiol & Cortical Excitability: Clinical Trial Findings`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 12, 2026](https://cedclinic.com/cannabis-regulatory-updates-march-2026/) Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [North Carolina advisory group recommends legalizing marijuana for adults – WXII](https://cedclinic.com/north-carolina-cannabis-legalization-advisory/) Learn about North Carolina's advisory group's recommendation to legalize marijuana for adults, reflecting evolving cannabis policies. [Read More](https://cedclinic.com/north-carolina-cannabis-legalization-advisory/) [Virginia Lawmakers And Governor 'Have A Deal' On Bill To Legalize Marijuana Sales This Month](https://cedclinic.com/virginia-lawmakers-and-governor-have-a-deal-on-bill-to-legalize-marijuana-sales-this-month/) Virginia's legislative progress on marijuana sales legalization highlights key regulatory developments in cannabis retail. [Explore Update](https://cedclinic.com/virginia-lawmakers-and-governor-have-a-deal-on-bill-to-legalize-marijuana-sales-this-month/) [Georgia House Passes Bill to Expand Medical Cannabis Program](https://cedclinic.com/georgia-medical-cannabis-expansion-bill/) Georgia's expansion of its [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) program signals growing acceptance and regulatory changes in cannabis access. [Learn More](https://cedclinic.com/georgia-medical-cannabis-expansion-bill/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).